F m Investments LLC Raises Stock Position in Eli Lilly and Company $LLY

F m Investments LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,860 shares of the company’s stock after acquiring an additional 52 shares during the period. Eli Lilly and Company comprises approximately 1.0% of F m Investments LLC’s investment portfolio, making the stock its 18th biggest holding. F m Investments LLC’s holdings in Eli Lilly and Company were worth $28,732,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the period. Laurel Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company in the second quarter worth about $8,827,714,000. Nuveen LLC purchased a new stake in Eli Lilly and Company in the first quarter worth about $4,613,912,000. Finally, Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Daiwa Capital Markets boosted their price objective on shares of Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. Sanford C. Bernstein increased their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research report on Monday. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Stock Down 0.4%

Shares of LLY stock opened at $1,105.45 on Friday. The stock’s fifty day moving average price is $882.95 and its 200 day moving average price is $797.01. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a market cap of $1.05 trillion, a price-to-earnings ratio of 72.25, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the company earned $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.